- Home
- EDIT vs CERS Comparison
EDIT vs CERS Comparison
Compare EDIT & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- CERS
- Stock Information
- Founded
- EDIT 2013
- CERS 1991
- Country
- EDIT United States
- CERS United States
- Employees
- EDIT N/A
- CERS N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- CERS EDP Services
- Sector
- EDIT Health Care
- CERS Technology
- Exchange
- EDIT Nasdaq
- CERS Nasdaq
- Market Cap
- EDIT 269.8M
- CERS 276.0M
- IPO Year
- EDIT 2016
- CERS 1997
- Fundamental
- Price
- EDIT $3.92
- CERS $1.57
- Analyst Decision
- EDIT Buy
- CERS Strong Buy
- Analyst Count
- EDIT 11
- CERS 2
- Target Price
- EDIT $4.56
- CERS $3.50
- AVG Volume (30 Days)
- EDIT 2.7M
- CERS 1.6M
- Earning Date
- EDIT 11-03-2025
- CERS 10-29-2025
- Dividend Yield
- EDIT N/A
- CERS N/A
- EPS Growth
- EDIT N/A
- CERS N/A
- EPS
- EDIT N/A
- CERS N/A
- Revenue
- EDIT $38,901,000.00
- CERS $192,510,000.00
- Revenue This Year
- EDIT N/A
- CERS $22.02
- Revenue Next Year
- EDIT N/A
- CERS $9.32
- P/E Ratio
- EDIT N/A
- CERS N/A
- Revenue Growth
- EDIT N/A
- CERS 13.25
- 52 Week Low
- EDIT $0.91
- CERS $1.12
- 52 Week High
- EDIT $4.05
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- EDIT 73.38
- CERS 61.25
- Support Level
- EDIT $3.01
- CERS $1.46
- Resistance Level
- EDIT $3.58
- CERS $1.61
- Average True Range (ATR)
- EDIT 0.30
- CERS 0.10
- MACD
- EDIT 0.10
- CERS 0.01
- Stochastic Oscillator
- EDIT 91.42
- CERS 78.72
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.